Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BYJournal of cancer science and clinical therapeutics

Actinic Keratosis: Current Concepts in Pathogenesis, Risk Stratification, Management, and Prevention

  1. 1Department of Translational Research, College of Osteopathic Medicine of the Pacific, Pomona, California 91766 USA
  2. 2Rush Medical College, Rush University, Chicago, Illinois 60612, USA

Abstract

Actinic keratosis (AK) is among the most frequently encountered premalignant skin lesions in clinical practice and is now widely regarded as part of the biologic spectrum that can progress to cutaneous squamous cell carcinoma (cSCC). The global prevalence of AK continues to increase because of aging populations, cumulative ultraviolet (UV) radiation exposure, and increasing survival of high-risk populations, highlighting its growing public health impact. Advances in molecular and cellular research have expanded the understanding of AK pathogenesis, demonstrating that chronic UV-induced DNA damage, oxidative stress, immune dysregulation, and field cancerization interact to drive the development and progression of dysplastic keratinocytes. Despite the availability of multiple lesion-directed and field-directed treatment options, management remains challenging because of disease recurrence, patient adherence, variability in treatment response, and the inability to reliably identify which lesions are most likely to progress to invasive cSCC. Emerging molecular biomarkers, genomic profiling, noninvasive imaging technologies, and novel therapeutic strategies have the potential to improve individualized risk assessment and treatment selection but require further clinical validation before widespread implementation. This critical review provides a comprehensive overview of the current understanding of AK, including its epidemiology, risk factors, pathogenesis, progression to cSCC, risk stratification, contemporary treatment approaches, barriers to effective management, preventive strategies, and future directions. Continued integration of molecular insights with patient-centered care may improve early detection, personalize therapeutic decision-making, and reduce the burden of keratinocyte carcinogenesis.

Related

  1. Stress Fractures in Military Recruits: Current Concepts, Risk Stratification, Prevention, Evidence-Based Management, and Future Directions
    Mohammed Al-Rumaih, Waleed Al-Hoshan, Mansour Al-Jahny +5
    CureusPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  2. Herpes Simplex Virus: Molecular Pathogenesis, Type-Specific Disease Burden, and Advances in Prevention and Treatment.
    Chenhao Jiang, Jianhui Nie, Li Zhang
    VirusesPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMC
  3. The Bidirectional Relationship Between Tuberculosis and Type 2 Diabetes Mellitus: Pathogenesis, Treatment Challenges, and Prevention Strategies
    Archana Banda, Kim Pedrigal, Savannah Jayne +1
    CureusPeer-reviewedCC BYFull textEpidemiology & public healthInfectious diseaseEurope PMCPMC
  4. Pulmonary Carcinoid Tumors (Lung Carcinoids): Current Concepts in Diagnosis and Management
    David L. Chan, Yuji Uehara, Keigo Kobayashi +1
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMC
  5. Atrial functional mitral regurgitation – current concepts in mechanisms, imaging, and management
    M. Peneva, K. Dzhinsov, T. Shalganov
    Българска кардиологияPeer-reviewedCC BYFull textCardiovascular medicineDOAJ
BibTeX
@article{sandhu2026actinic,
  title = {{Actinic Keratosis: Current Concepts in Pathogenesis, Risk Stratification, Management, and Prevention}},
  author = {Amrita Sandhu and Chiamaka C Ogbuefi and Devendra K Agrawal},
  journal = {Journal of cancer science and clinical therapeutics},
  year = {2026},
  month = sep,
  doi = {10.26502/jcsct.5079289},
  url = {https://doi.org/10.26502/jcsct.5079289},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Actinic Keratosis: Current Concepts in Pathogenesis, Risk Stratification, Management, and Prevention
AU  - Amrita Sandhu
AU  - Chiamaka C Ogbuefi
AU  - Devendra K Agrawal
PY  - 2026
DA  - 2026/09/02
JO  - Journal of cancer science and clinical therapeutics
DO  - 10.26502/jcsct.5079289
UR  - https://doi.org/10.26502/jcsct.5079289
AB  - Actinic keratosis (AK) is among the most frequently encountered premalignant skin lesions in clinical practice and is now widely regarded as part of the biologic spectrum that can progress to cutaneous squamous cell carcinoma (cSCC). The global prevalence of AK continues to increase because of aging populations, cumulative ultraviolet (UV) radiation exposure, and increasing survival of high-risk populations, highlighting its growing public health impact. Advances in molecular and cellular research have expanded the understanding of AK pathogenesis, demonstrating that chronic UV-induced DNA damage, oxidative stress, immune dysregulation, and field cancerization interact to drive the development and progression of dysplastic keratinocytes. Despite the availability of multiple lesion-directed and field-directed treatment options, management remains challenging because of disease recurrence, patient adherence, variability in treatment response, and the inability to reliably identify which lesions are most likely to progress to invasive cSCC. Emerging molecular biomarkers, genomic profiling, noninvasive imaging technologies, and novel therapeutic strategies have the potential to improve individualized risk assessment and treatment selection but require further clinical validation before widespread implementation. This critical review provides a comprehensive overview of the current understanding of AK, including its epidemiology, risk factors, pathogenesis, progression to cSCC, risk stratification, contemporary treatment approaches, barriers to effective management, preventive strategies, and future directions. Continued integration of molecular insights with patient-centered care may improve early detection, personalize therapeutic decision-making, and reduce the burden of keratinocyte carcinogenesis.
SN  - 2637-5079
ER  -